A Phase 2/3 interventional study of Relatlimab and Nivolumab in Melanoma, sponsored by Bristol-Myers Squibb. Active, not recruiting at 127 sites in 25 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by Bristol-Myers Squibb · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Melanoma by Bristol-Myers Squibb — 3 open to participants now, 9 under way, 3 of them phase 3. Melanoma · Bristol-Myers Squibb.
Among the 111 studies in Melanoma by Bristol-Myers Squibb, this one is the 12th largest by enrollment of the 75 interventional ones that give a count, is one of 5 that started in 2018, is one of 2 in phase 2/3, and was the 85th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →3 of the 111 studies in Melanoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Belgium, Canada and 10 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Australia, Canada and 5 more countries
Ages 18+
Bristol-Myers Squibb · Sites in India
Ages 12+
By country, each count listing its studies:
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 33 · Phase 3 23 · Phase 4 1
First in 2002; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 714 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 107 across the 75 interventional studies, 366 across the 32 observational. Of the 90 that completed or were terminated, 41 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
1 of the studies in Melanoma by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04550247Bristol-Myers SquibbA Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France | 2027-03-15 |
Add it to your calendar (.ics) → With an account.
Among the 111 studies in Melanoma by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma or melanoma that has spread.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination
Biological: Relatlimab · Biological: Nivolumab
Monotherapy
Biological: Nivolumab
Specified dose on specified day
Specified dose on specified days
Progression Free Survival (PFS)
Progression Free Survival (PFS) is defined as the time between the date of randomization and the date of first documented tumor progression, assessed by a blinded independent central review (BICR) (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first. Subjects who die without a reported progression will be considered to have progressed on the date of their death.
Time frame: From randomization to date of first documented tumor progression or death (up to approximately 33 months)
Overall Survival (OS)
Overall Survival (OS) is defined as the time between the date of randomization and the date of death due to any cause. For subjects that are alive, their survival time will be censored at the date of last contact ("last known alive date").
Time frame: From randomization to the date of death (up to approximately 3 years)
Overall Response Rate (ORR)
Objective response rate (ORR) is defined as the number of randomized subjects who achieve a best response of complete response (CR) or partial response (PR) based on BICR assessments (using RECIST v1.1 criteria).
Time frame: From randomization up to approximately 3 years
The Number of Participants Experiencing Adverse Events (AEs)
The number of participants experiencing adverse events (AEs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 33 months)
The Number of Participants Experiencing Serious Adverse Events (SAEs)
The number of participants experiencing serious adverse events (SAEs). A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.
Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 33 months)
The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
The number of participants experiencing adverse events (AEs) leading to discontinuation. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 33 months)
The Number of Participant Deaths in the Study
The number of participant deaths in the study.
Time frame: From first dose up to approximately 33 months
The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests
The number of participants with clinical laboratory test abnormalities in specific liver tests based on US conventional units.
Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 33 months)
The Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests
The number of participants with clinical laboratory test abnormalities in specific thyroid tests based on US conventional units.
Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 33 months)
| Milestone | Arm A: Relatlimab + Nivolumab | Arm B: Nivolumab |
|---|---|---|
| Started | 355 | 359 |
| Completed | 237 | 227 |
| Not completed | 118 | 132 |
| Withdrew: Death | 107 | 118 |
| Withdrew: Lost to follow-up | 5 | 5 |
| Withdrew: Participant withdrew consent | 4 | 9 |
| Withdrew: Other reasons | 1 | 0 |
| Withdrew: Not reported | 1 | 0 |
Progression Free Survival (PFS) is defined as the time between the date of randomization and the date of first documented tumor progression, assessed by a blinded independent central review (BICR) (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first. Subjects who die without a reported progression will be considered to have progressed on the date of their death.
| Months | Arm A: Relatlimab + Nivolumab | Arm B: Nivolumab |
|---|---|---|
| Progression Free Survival (PFS) | 10.12 (6.37 to 15.74) | 4.63 (3.38 to 5.62) |
Overall Survival (OS) is defined as the time between the date of randomization and the date of death due to any cause. For subjects that are alive, their survival time will be censored at the date of last contact ("last known alive date").
Results for this outcome have not been posted.
Objective response rate (ORR) is defined as the number of randomized subjects who achieve a best response of complete response (CR) or partial response (PR) based on BICR assessments (using RECIST v1.1 criteria).
Results for this outcome have not been posted.
The number of participants experiencing adverse events (AEs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | Arm A: Relatlimab + Nivolumab | Arm B: Nivolumab |
|---|---|---|
| The Number of Participants Experiencing Adverse Events (AEs) | 345 | 339 |
The number of participants experiencing serious adverse events (SAEs). A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.
| Participants | Arm A: Relatlimab + Nivolumab | Arm B: Nivolumab |
|---|---|---|
| The Number of Participants Experiencing Serious Adverse Events (SAEs) | 121 | 105 |
The number of participants experiencing adverse events (AEs) leading to discontinuation. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | Arm A: Relatlimab + Nivolumab | Arm B: Nivolumab |
|---|---|---|
| The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 69 | 41 |
The number of participant deaths in the study.
| Participants | Arm A: Relatlimab + Nivolumab | Arm B: Nivolumab |
|---|---|---|
| The Number of Participant Deaths in the Study | 108 | 119 |
The number of participants with clinical laboratory test abnormalities in specific liver tests based on US conventional units.
| Participants | Arm A: Relatlimab + Nivolumab | Arm B: Nivolumab |
|---|---|---|
| ALT OR AST > 3XULN | 26 | 15 |
| ALT OR AST> 5XULN | 11 | 7 |
| ALT OR AST> 10XULN | 4 | 4 |
| ALT OR AST > 20XULN | 0 | 2 |
| TOTAL BILIRUBIN > 2XULN | 2 | 5 |
| ALP > 1.5xULN | 34 | 30 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>1.5XULN IN 1 DAY | 2 | 2 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>1.5XULN IN 30 DAYS | 2 | 2 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY | 2 | 1 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS | 2 | 1 |
The number of participants with clinical laboratory test abnormalities in specific thyroid tests based on US conventional units.
| Participants | Arm A: Relatlimab + Nivolumab | Arm B: Nivolumab |
|---|---|---|
| TSH > ULN | 106 | 106 |
| TSH > ULN WITH TSH <= ULN AT BASELINE | 84 | 82 |
| TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN | 63 | 48 |
| TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN | 7 | 7 |
| TSH > ULN WITH FT3/FT4 TEST MISSING | 8 | 9 |
| TSH < LLN | 89 | 84 |
| TSH <LLN WITH TSH >= LLN AT BASELINE | 79 | 78 |
| TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN | 51 | 40 |
| TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN | 6 | 3 |
| TSH < LLN WITH FT3/FT4 TEST MISSING | 11 | 7 |
Collected over From first dose to up to 100 days post last dose (up to approximately 33 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Relatlimab + Nivolumab | 108/355 (30.4%) | 155/355 (43.7%) | 314/355 (88.5%) |
| Arm B: Nivolumab | 119/359 (33.1%) | 140/359 (39%) | 298/359 (83%) |
| Event | Arm A: Relatlimab + Nivolumab | Arm B: Nivolumab |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 39/355 | 47/359 |
| General physical health deteriorationGeneral disorders | 2/355 | 6/359 |
| Urinary tract infectionInfections and infestations | 3/355 | 6/359 |
| AnaemiaBlood and lymphatic system disorders | 5/355 | 4/359 |
| Adrenal insufficiencyEndocrine disorders | 5/355 | 0/359 |
| ColitisGastrointestinal disorders | 5/355 | 1/359 |
| PneumoniaInfections and infestations | 5/355 | 3/359 |
| PyrexiaGeneral disorders | 3/355 | 5/359 |
| Acute myocardial infarctionCardiac disorders | 4/355 | 2/359 |
| MyocarditisCardiac disorders | 4/355 | 1/359 |
| Event | Arm A: Relatlimab + Nivolumab | Arm B: Nivolumab |
|---|---|---|
| FatigueGeneral disorders | 104/355 | 74/359 |
| PruritusSkin and subcutaneous tissue disorders | 88/355 | 62/359 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 84/355 | 54/359 |
| DiarrhoeaGastrointestinal disorders | 82/355 | 62/359 |
| HeadacheNervous system disorders | 64/355 | 47/359 |
| NauseaGastrointestinal disorders | 63/355 | 59/359 |
| RashSkin and subcutaneous tissue disorders | 62/355 | 49/359 |
| HypothyroidismEndocrine disorders | 58/355 | 47/359 |
| Decreased appetiteMetabolism and nutrition disorders | 55/355 | 27/359 |
| AnaemiaBlood and lymphatic system disorders | 50/355 | 37/359 |
| Age, Continuous(years) | Arm A: Relatlimab + Nivolumab | Arm B: Nivolumab | Total |
|---|---|---|---|
| Mean | 61.2 ± 14.1 | 61.2 ± 14.0 | 61.2 ± 14.0 |
| Sex: Female, Male(Participants) | Arm A: Relatlimab + Nivolumab | Arm B: Nivolumab | Total |
|---|---|---|---|
| Female | 145 | 153 | 298 |
| Male | 210 | 206 | 416 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Relatlimab + Nivolumab | Arm B: Nivolumab | Total |
|---|---|---|---|
| Hispanic or Latino | 27 | 20 | 47 |
| Not Hispanic or Latino | 144 | 147 | 291 |
| Unknown or Not Reported | 184 | 192 | 376 |
| Race (NIH/OMB)(Participants) | Arm A: Relatlimab + Nivolumab | Arm B: Nivolumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 5 | 5 |
| White | 342 | 348 | 690 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 13 | 5 | 18 |
Showing the first 100 of 127 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2018 to primary completion in Jan 2021, 33 months.
Results were first posted in Mar 2022, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.